Showing 811-820 of 2874 results for "".
Clinical Commentary: Stroke Care Reshuffles During COVID-19 Pandemic
https://practicalneurology.com/diseases-diagnoses/stroke/clinical-commentary-stroke-care-reshuffles-during-covid-19-pandemic/31711/“Time Is Brain” still applies.Six Steps to Reduce Taxes on Investments
https://practicalneurology.com/columns/practice-management/six-steps-to-reduce-taxes-on-investments/30478/In today's volatile tax environment, successful investment requires an emphasis on strategic after-tax asset growth.Improving Your After-Tax Financial Efficiency
https://practicalneurology.com/columns/practice-management/improving-your-after-tax-financial-efficiency/30377/Solution: ALS
https://practicalneurology.com/diseases-diagnoses/neuromuscular/solution-als/30655/Last month's case presented dysarthria and positive myasthenia serology.Incorporating FcRn Inhibitors Into Clinical Practice in Chronic Inflammatory Demyelinating Polyneuropathy
https://practicalneurology.com/programs/cme/incorporating-fcrn-inhibitors-into-clinical-practice-in-chronic-inflammatory-demyelinating-polyneuropathy/27135/Tune in to learn more about how to incorporate FcRn inhibitors into clinical practice for inflammatory demyelinating polyneuropathy (CIDP).The Evolving Role of Neurologists Amid the Endovascular Revolution in Stroke Care
https://practicalneurology.com/diseases-diagnoses/stroke/the-evolving-role-of-neurologists-amid-the-endovascular-revolution-in-stroke-care/30391/New standards of care are shaping a brighter future in stroke treatment, but many challenges remain.Improving Outcomes Earlier in Generalized Myasthenia Gravis: Roadmap for Incorporating Targeted Therapies Into Clinical Practice
https://practicalneurology.com/programs/cme/improving-outcomes-earlier-in-generalized-myasthenia-gravis-roadmap-for-incorporating-targeted-therapies-into-clinical-practice/29145/While traditional gMG treatments bring many debilitating side effects, a more targeted approach focusing on the FcRn complex has shown great promise.Update in Epilepsy Therapeutics
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/update-in-epilepsy-therapeutics/30511/In addition to comorbid conditions and side effects, cost and availability should factor into therapeutic selection.In the Pipeline
https://practicalneurology.com/columns/practice-management/in-the-pipeline/30821/Opportunities for Patients Arising From Practicalities of Health Care
https://practicalneurology.com/archives/2018-feb/opportunities-for-patients-arising-from-practicalities-of-health-care/30273/